Sorry, you need to enable JavaScript to visit this website.

A study to assess the general safety and effect of gemtuzumab ozogamicin (MYLOTARG™) on the heart of patients with CD33-positive acute myeloid leukemia and to see how the drug moves through the body

A study to assess the general safety and effect of gemtuzumab ozogamicin (MYLOTARG™) on the heart of patients with CD33-positive acute myeloid leukemia and to see how the drug moves through the body. A single-arm, open-label, phase 4 study evaluating QT interval, pharmacokinetics, and safety of gemtuzumab
ozogamicin (MYLOTARG™) as a single-agent regimen in patients with relapsed or refractory CD33-positive acute myeloid leukemia

Category & Conditions: Cancer
Medicine: MYLOTARG™(GEMTUZUMAB OZOGAMICIN FOR INJECTION)
ClinicalTrials.gov Identifier (NCT): NCT03727750
Protocol ID: B1761031
    Share
PrintDownload
Open Plain Language Summary Result: Click here